KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Novavax (NVAX) Receivables - Net (2016 - 2025)

Novavax has reported Receivables - Net over the past 14 years, most recently at $114.1 million for Q4 2025.

  • Quarterly results put Receivables - Net at $114.1 million for Q4 2025, up 5.39% from a year ago — trailing twelve months through Dec 2025 was $114.1 million (up 5.39% YoY), and the annual figure for FY2025 was $114.1 million, up 5.39%.
  • Receivables - Net for Q4 2025 was $114.1 million at Novavax, up from $34.2 million in the prior quarter.
  • Over the last five years, Receivables - Net for NVAX hit a ceiling of $478.2 million in Q1 2022 and a floor of $34.2 million in Q3 2025.
  • Median Receivables - Net over the past 5 years was $113.5 million (2023), compared with a mean of $177.1 million.
  • Peak annual rise in Receivables - Net hit 740.37% in 2022, while the deepest fall reached 78.85% in 2022.
  • Novavax's Receivables - Net stood at $455.0 million in 2021, then tumbled by 78.85% to $96.2 million in 2022, then skyrocketed by 216.93% to $304.9 million in 2023, then plummeted by 64.49% to $108.3 million in 2024, then rose by 5.39% to $114.1 million in 2025.
  • The last three reported values for Receivables - Net were $114.1 million (Q4 2025), $34.2 million (Q3 2025), and $226.4 million (Q2 2025) per Business Quant data.